Terms: = Prostate cancer AND MAF, MGC71685, 4094, ENSG00000178573 AND Treatment
6 results:
1. Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical prostate cancer treatment: A Pan prostate cancer Group Study.
Burns D; Anokian E; Saunders EJ; Bristow RG; Fraser M; Reimand J; Schlomm T; Sauter G; Brors B; Korbel J; Weischenfeldt J; Waszak SM; Corcoran NM; Jung CH; Pope BJ; Hovens CM; Cancel-Tassin G; Cussenot O; Loda M; Sander C; Hayes VM; Dalsgaard Sorensen K; Lu YJ; Hamdy FC; Foster CS; Gnanapragasam V; Butler A; Lynch AG; Massie CE; ; Woodcock DJ; Cooper CS; Wedge DC; Brewer DS; Kote-Jarai Z; Eeles RA
Eur Urol; 2022 Aug; 82(2):201-211. PubMed ID: 35659150
[TBL] [Abstract] [Full Text] [Related]
2. The HOXB13 variant X285K is associated with clinical significance and early age at diagnosis in African American prostate cancer patients.
Na R; Wei J; Sample CJ; Gielzak M; Choi S; Cooney KA; Rabizadeh D; Walsh PC; Zheng LS; Xu J; Isaacs WB
Br J Cancer; 2022 Mar; 126(5):791-796. PubMed ID: 34799695
[TBL] [Abstract] [Full Text] [Related]
3. Differential Actions of Estrogen Receptor α and β via Nongenomic Signaling in Human prostate Stem and Progenitor Cells.
Majumdar S; Rinaldi JC; Malhotra NR; Xie L; Hu DP; Gauntner TD; Grewal HS; Hu WY; Kim SH; Katzenellenbogen JA; Kasper S; Prins GS
Endocrinology; 2019 Nov; 160(11):2692-2708. PubMed ID: 31433456
[TBL] [Abstract] [Full Text] [Related]
4. Diverse roles of the E2/E3 hybrid enzyme UBE2O in the regulation of protein ubiquitination, cellular functions, and disease onset.
Ullah K; Zubia E; Narayan M; Yang J; Xu G
FEBS J; 2019 Jun; 286(11):2018-2034. PubMed ID: 30468556
[TBL] [Abstract] [Full Text] [Related]
5. prostate cancer gene expression signature of patients with high body mass index.
Sharad S; Srivastava A; Ravulapalli S; Parker P; Chen Y; Li H; Petrovics G; Dobi A
Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):22-9. PubMed ID: 21060327
[TBL] [Abstract] [Full Text] [Related]
6. Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors.
Hofer MD; Fecko A; Shen R; Setlur SR; Pienta KG; Tomlins SA; Chinnaiyan AM; Rubin MA
Neoplasia; 2004; 6(5):503-12. PubMed ID: 15548358
[TBL] [Abstract] [Full Text] [Related]
